Expert: Professor Jorge Cortes Georgia Cancer Centre, Augusta (USA)

Program:
Overview of significant clinical aspects presented during the meeting, including:

• Update on the iCMLf CANDID study - COVID-19 in patients with CML
• Treatment-free remission
  
  • Final report of the EURO-SKI study
  • Interim results of the Russian Prospective Study of Reduction and Discontinuation of TKI
  • Mathematical modeling on risk of relapses and withdrawal syndrom
• Updates on clinical studies
  • Final report of the BYOND study (bosutinib in previously treated patients)
  • Primary analysis of the OPTIC trial (Dose-optimization study of 3 starting doses of ponatinib)
  • Post-hoc analysis of DASISION: Effect of comorbidities on response outcomes:
  • Updated results of Phase 1 study with new agent vodobatinib
• Incidence of pleural effusions with dasatinb and effect of switching to bosutinib

Q&A Session